Plump: Oncology great advances in enrollment, great examples of umbrella and basket trials to help control costs #Genomicsfest
1:30pm October 3rd 2017 via Hootsuite
Plump: As CMO/CSO, help drive reimb; help manage 'outrageous, absurd costs of clinical trials'; how to leverage capabilities #Genomicsfest
1:28pm October 3rd 2017 via Hootsuite
Plenge: With a genetic target - PSKC9 a poster child, but it is excreted, had choices. Other targets not so 'conventional' #Genomicsfest
1:26pm October 3rd 2017 via Hootsuite
Q: Is it gaps in science, or a cultural problem? Plenge: Modalities that we knew what to do with (small molecules or Abs) #Genomicsfest
Plenge: Also reduce cycle-time bet. an idea, and testing in humans. Today: longer as the many more things to consider, complex #Genomicsfest
1:24pm October 3rd 2017 via Hootsuite
John: Success rates have already shown to be higher - on the order of 20% compared to about 10% without genetic guidance #Genomicsfest
1:23pm October 3rd 2017 via Hootsuite
Sally John (Biogen) Robert Plenge (Celgene) Andy Plump (Takeda) moderator Madeem Sarwar (Eisai AiM) #genomicsfest
1:22pm October 3rd 2017 via Hootsuite
@rplenge and panel at #genomicsfest - “a Dream Team” https://t.co/zEmHBhLtro
1:20pm October 3rd 2017 via Hootsuite
Panel: Human genetics guided drug development: from insight to impact #Genomicsfest
1:19pm October 3rd 2017 via Hootsuite
Q: What % for cancer is self-pay, inst.-absorbed? How changed? Daber: very few (<1%) self-paid. Inh cancer DTC self-paid #Genomicsfest
11:54am October 3rd 2017 via Hootsuite
Lennerz: Even if 100% out of pocket - still no one knows! #Genomicsfest
11:52am October 3rd 2017 via Hootsuite
Lennerz: Out-of-pocket costs difficult to determine. Example: child with need for rare genetic testing. No one knows price #Genomicsfest
Daber: One problem:consistency in interpretation. Also organizing operations - billing, payments, all done by humans now #Genomicsfest
11:50am October 3rd 2017 via Hootsuite
Q: Informatics challenges for development? Ramamurthy: Processes that evaluate effectiveness, to do that faster #Genomicsfest
11:49am October 3rd 2017 via Hootsuite
Q: How many policies? Dodek: Mass Blue Cross had over 500 plans; managing over-use and expense #Genomicsfest
11:47am October 3rd 2017 via Hootsuite
Dodek: Wants to be current w/network physicians as well; labor-intensive process #Genomicsfest
11:46am October 3rd 2017 via Hootsuite
Q: Imtc of evidence - what matters in coverage? Dodek: Looks for peer-review, solid rigor, no one health plan has expertise #Genomicsfest
11:45am October 3rd 2017 via Hootsuite
Daber: We are working with existing systems that are just not setup to handle this kind of data; thus a big problem to solve #Genomicsfest
11:40am October 3rd 2017 via Hootsuite
Daber: A aancy-looking report as a PDF in an EHR: not accessible. How can a platform organize it, evaluate usefulness? #Genomicsfest
11:38am October 3rd 2017 via Hootsuite
Ramamurthy: $FMI has sequenced hundreds of thousands of patients. Enables potential clinical trial enrollment #Genomicsfest
11:37am October 3rd 2017 via Hootsuite
Lennerz: Putting the technical achievement in perspective: 20y to a week or two for WGS. $3B cost vs about $1K #Genomicsfest
11:35am October 3rd 2017 via Hootsuite
Storts: The technology has increased by leaps and bounds. But the complexity of the biological systems 'is just overwhelming' #Genomicsfest
11:33am October 3rd 2017 via Hootsuite
Lu: Pt affordability (plan members), an issue of cost-sharing, copayment (unclear to pt), deductibles and co-ins all related #Genomicsfest
11:29am October 3rd 2017 via Hootsuite
Lu: Payers try to consider genomic medicine; coding a big challenge as part of implementation, and comes down to pricing #Genomicsfest
11:28am October 3rd 2017 via Hootsuite
Dodek: It can take years to get a code; 1 code for 1-49 genes, etc. w/bundled payments. #Genomicsfest
11:26am October 3rd 2017 via Hootsuite
From Putting the G in Genome: financial sustainability of genomic medicine at #genomicsfest Bob Daber (Genosity) on… https://t.co/xjlACZN3E4
Dodek: Technology advancing faster than health care plan's ability to evaluate it. A code w/no std reimbursement. #Genomicsfest
11:23am October 3rd 2017 via Hootsuite
Dodek: Everyone wants quality healthcare, but if costs are consistently higher than inflation, a problem. #Genomicsfest
11:22am October 3rd 2017 via Hootsuite
Dodek: Health plans get a bad reputation for denying payment; however there's resp. to provide quality of care w/wise spending #Genomicsfest
11:21am October 3rd 2017 via Hootsuite
Daber: More is better but the payers need to pay for established markers, not research. Small labs don't have infrastructure #Genomicsfest
11:20am October 3rd 2017 via Hootsuite
Daber: A 'human pipeline' to handle workflow. So much content, costs become a challenge; also differentiated value a question #Genomicsfest
11:19am October 3rd 2017 via Hootsuite
Daber: Early on w/NGS, focus on getting the lab going, lots of effort involved. Much infrastructure needed for payments #Genomicsfest
11:17am October 3rd 2017 via Hootsuite
Ramamurthy: Feels that payors are improving, see increased clinical utility of diagnostics. Validity: by FDA. Payers: utility #Genomicsfest
11:16am October 3rd 2017 via Hootsuite
Lennerz 'biggest impediment: obtaining reimbursement'. Ramamurthy: has been both on regulatory and reimb sides. #Genomicsfest
11:14am October 3rd 2017 via Hootsuite
Doug Storts (Promega) Research reagents provider from 1978; increasingly for applied markets (forensics). No FDA-cleared prods #Genomicsfest
11:11am October 3rd 2017 via Hootsuite
hristine Lu (Harvard) Looks at policy, use of health care, outcomes and EHR #Genomicsfest
11:10am October 3rd 2017 via Hootsuite
Dodek (Neighborhood Health Care) Pediatrician, knows about financing of new technology; health plans struggle w/ reimbursement #Genomicsfest
11:09am October 3rd 2017 via Hootsuite
Bob Daber (Genosity) Geneticist, has built many labs from scratch; Bio-Reference and GeneDx before this; UPenn #Genomicsfest
11:08am October 3rd 2017 via Hootsuite
Lakshman Ramamurthy (Foundation Medicine) #Genomicsfest Before FMI, was adviser at CMS on coverage issues, FDA before that, and industry
11:06am October 3rd 2017 via Hootsuite
Lennerz: introduces the topic with slide from '16 JMD https://t.co/4YvDYu1o2n Panel comes from diverse perspectives #Genomicsfest
Jochen Lennerz (MGH), Christine Lu (Harvard), Doug Storts (Promega), L. Ramamurthy (Foundation Medicine), Bob Daber (Genosity) #Genomicsfest
11:04am October 3rd 2017 via Hootsuite
Panel Discussion: Putting the G in Genome: Financial sustainability of genomic medicine #Genomicsfest
11:03am October 3rd 2017 via Hootsuite
Henderson: Lasso regularization: many features with very small variation; case where it shows up in regression analysis #Genomicsfest
10:02am October 3rd 2017 via Hootsuite
Henderson: Other 20 have variation, last 20 do not vary. Lasso finds five important, and one w/zero variance via lasso #Genomicsfest
10:01am October 3rd 2017 via Hootsuite
Henderson: A binary outcome, using penalized regression and lasso. Of 45 biomarkers, 5 predict outcome (model) #Genomicsfest
10:00am October 3rd 2017 via Hootsuite
Henderson: Std assays - genotyping, imputed SNPs, gene exp. Lots of features - much to filter out. Will go through process #Genomicsfest
9:59am October 3rd 2017 via Hootsuite
Henderson: Have seen companion diagnostics (CDx) projects in addition to methylation, metabolomic, genomic, expression data #Genomicsfest
9:58am October 3rd 2017 via Hootsuite
Henderson: Statistical geneticists for pharma; '14 started group analyzing data for pharma (genetics / genomics). #Genomicsfest
9:57am October 3rd 2017 via Hootsuite
David Henderson (Axio Research): Creating biomarker panels for diagnostics using high dimensional assays #Genomicsfest
9:56am October 3rd 2017 via Hootsuite
Nelson: GRC is non-profit cross-pharma consortia, focused on EHR-linked biobank data. 'Genetics isn't the end-all' can do more #Genomicsfest
9:54am October 3rd 2017 via Hootsuite
